In the other report, Celgene Inc. 's Revlimid doubled the number of myeloma patients whose disease remained in remission three years after treatment began, compared with those on placebo.
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.